您好, 歡迎來(lái)到化工儀器網(wǎng)! 登錄| 免費(fèi)注冊(cè)| 產(chǎn)品展廳| 收藏商鋪|
Carbapenem-resistant Klebsiella pneumoniae (CRKP)感染小鼠模型,全肺臟流式檢測(cè)分群圈門(mén)策略,可以參考下圖。Gating strategy for determining the myeloid and lymphoid subsets in the whole lungs of control and Trpv1DTA mice after 48h of clodronate liposome (CLL) administration. PBS-liposome (PBL) was used for control group of mice. CLL or PBL (70 μL/mouse) was inoculated via intratracheal route at 48 hours before the immune cell type analyses. 單核巨噬清除訂購(gòu)信息見(jiàn)后。
(A) Gating strategy for determining the myeloid and lymphoid subsets in the whole lungs of control and Trpv1DTA mice after 48h of clodronate liposome (CLL) administration. PBS-liposome (PBL) was used for control group of mice. CLL or PBL (70 μL/mouse) was inoculated via intratracheal route at 48 hours before the immune cell type analyses. Interstitial macrophages (IMs, CD45+Siglec-F–CD11b+Ly6G– F4/80+ cells), neutrophils (CD45+Siglec-F–CD11b+Ly6G+ cells), Ly6Chi monocytes (CD45+Siglec-F–CD11b+Ly6G– F4/80– Ly6Chi cells), Ly6Clo monocytes (CD45+Siglec-F–CD11b+Ly6G–F4/80–Ly6Clo cells), CD11b+ DC (CD45+Siglec-F–CD11b+Ly6G– F4/80–Ly6C– CD11c+ MHC-II+cells), CD11b– DCs (CD45+Siglec-F–CD11b– CD3– B220– NK1.1– CD11c+ MHC-II+cells), B cells (CD45+Siglec-F–CD11b– CD3–NK1.1–B220+cells), CD4+ T cells (CD45+Siglec-F–CD11b– CD3+ CD8–CD4+ cells), CD8+ T cells (CD45+Siglec-F–CD11b– CD3+ CD4–CD8+ cells) and CD4– CD8– T cells (CD45+Siglec-F–CD11b– CD3+ CD4–CD8– cells).
(B) Absolute numbers of myeloid and lymphoid subsets in the whole lungs of CLL- or PBL-treated control (n=3-4) and Trpv1DTA (n=3) mice after 48h of treatment.
(C) The BALF number of Ly6Chi monocytes, neutrophils, and AMs in CLL- and PBL-treated control (n=4) and Trpv1DTA mice (n=3-4) after 24h of CRKP infection. Statistical analysis: Mann Whitney test (B, left), unpaired ttests (B, right and C to E) with the following significance levels: (*P<0.05, **P<0.01,***P<0.001). ns, not significant.
品牌:Liposoma
產(chǎn)地:荷蘭
貨號(hào):CP-005-005
規(guī)格:5ml+5ml
品名:Clodronateliposomes & Control Liposomes
代理:靶點(diǎn)科技
部位:肺臟
細(xì)胞:肺泡巨噬細(xì)胞(AM)
劑量:70ul
方式:滴鼻(intratracheal administration)
時(shí)間點(diǎn):建模前48h
題目:Lung-innervating nociceptor sensory neurons promote pneumonic sepsis during carbapenem-resistant Klebsiella pneumoniae lung infection
期刊:SCIENCE ADVANCES
時(shí)間:6 Sep 2024
期卷:Vol 10, Issue 36
鏈接:DOI: 10.1126/sciadv.adl6162
Liposoma巨噬細(xì)胞清除劑氯膦酸二鈉脂質(zhì)體清除肺泡巨噬細(xì)胞AM:
請(qǐng)輸入賬號(hào)
請(qǐng)輸入密碼
請(qǐng)輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購(gòu)買(mǎi)風(fēng)險(xiǎn),建議您在購(gòu)買(mǎi)產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。